The ampersand is a design device used to communicate the interdisciplinary and collaborative research at York University.

External Funding Opportunity

DOD CDMRP Program Announcements - Part 2

The following funding opportunities are in the areas of Amyotrophic Sclerosis, Bone Marrow Failure, Gulf War Illness, Multiple Sclerosis and Ovarian Cancer research.  Summaries of each award mechanism are provided below.  Detailed descriptions of each funding mechanism and submission requirements can be found in the Program Announcements which are available electronically for downloading from the following web sites:
 
Grants.gov web site: http://www.grants.gov
 
The CDMRP web site: http://cdmrp.army.mil/funding/prgdefault.shtml and
 
The CDMRP eReceipt web site: https://cdmrp.org/
 
 
AMYOTROPHIC LATERAL SCLEROSIS (ALS) RESEARCH PROGRAM
 
1) Therapeutic Development Award – (Funding Opportunity No.:
 W81XWH-12-ALSRP-TDA)
 
Objectives
To promote the introduction of improved therapies for ALS by encouraging ALS investigators to undertake preclincial studies of novel and existing agents.
 
Note: Clinical trials will not be supported with this program announcement/funding opportunity. 
 
Applications must focus on one or more of the following areas in order to be considered for funding:
 
·         Development and/or validation of high-throughput screens to define targets with therapeutic potential or to identify lead agents for ALS treatment and be an asset for the ALS research community;
·         Development, modification, and/or validation of preclinical model systems in order to assess lead compounds and potential therapeutics by pharmacological and/or pharmacokinetic testing. Such models would also serve as improved tools for the ALS research community;
·         Development and optimization of pharmacologic agents through Adsorption, Distribution, Metabolism, Excretion (ADME) studies, and toxicology testing, including Investigational New Drug (IND)-enabling pharmacology/toxicology testing;
·         Formulation and stability studies, design and implementation of full-scale, pilot current Good Manufacturing Practice (cGMP) production of therapeutics and/or delivery systems for use in advanced preclinical and initial clinical trials;
·         Development of pharmacologic agents up to IND submission in order to initiate Phase I clinical trials after the award’s completion.
 
Value
Up to $1.5M
 
Duration
Up to 3 years
 
Deadlines
Full application to ORS – July 10, 2012
Pre-application submission deadline - April 9, 2012, 5:00 p.m. Eastern time (ET)
Full application to agency (by invitation only) – July 24, 2012, 11:59 p.m. ET
 
Please consult the following web site for further information on this opportunity and how to apply:
http://cdmrp.army.mil/funding/pa/12alsrptda_pa.pdf


2) Therapeutic Idea Award (Funding Opportunity No.: W81XWH-12-ALSRP-TIA)
 
Objectives

• To promote new ideas that are still in the early stages of development with the potential to yield highly impactful data and new avenues of investigation for novel therapeutics for ALS treatment; and
• To support conceptually innovative high-risk/high-reward research that could ultimately lead to critical discoveries or major advancement in ALS therapeutics.

 
Value
Up to $400,000 plus indirect costs
 
Duration
Up to 2 years
 
Deadlines
Full application to ORS – July 10, 2012
Pre-application submission deadline – April 9, 2012, 5:00 p.m. Eastern time (ET)
Full application to agency (by invitation only) – July 24, 2012, 11:59 p.m. ET
 
Please consult the following web site for further information on this opportunity and how to apply:
http://cdmrp.army.mil/funding/pa/12alsrptia_pa.pdf
 
 
BONE MARROW FAILURE RESEARCH PROGRAM (BMFRP)
 
1)      Idea Award (Funding Opportunity Number: W81XWH-12-BMFRP-IA)
 
Objectives

• To support innovative ideas and high-impact approaches to BMF research to move toward the BMFRP vision of understanding and curing BMF diseases; and
• To support new ideas, not ideas that are extensions of existing work. Proposed research studies should have a high probability of revealing new avenues of investigation. Research projects should include a well-formulated, testable hypothesis based on strong scientific rationale.

 
Value
Up to $360K plus indirect costs
 
Duration
Up to 3 years
 
Deadlines
Full application to ORS – July 2, 2012
Pre-application to agency – April 18, 2012, 5:00 p.m. (ET)
Full application to agency (by invitation only) – July 16, 2012
 
Please consult the following web site for further information on this opportunity and how to apply:
http://cdmrp.army.mil/funding/pa/12bmfrpidea_pa.pdf
 
 
GULF WAR ILLNESS RESEARCH PROGRAM (GWIRP)
 
1) Investigator-Initiated Research Award (Funding Opportunity No.: W81XWH-12-GWIRP-IIRA)
Objectives
To support research focusing on the complex of symptoms known as Gulf War Illness (GWI), improving its definition and diagnosis, characterizing disease symptoms, and better understanding its pathobiology. It is intended to encourage basic through clinical research aimed at identification of objective measures to distinguish ill from healthy veterans (e.g., biomarkers), elucidate potential treatment targets for GWI, or improve understanding of the pathobiology underlying GWI symptoms. In addition, studies that characterize chronic effects of neurotoxic exposures at dosage comparable to that encountered during the Gulf War are acceptable. The IIRA provides investigators a mechanism to establish proof of principle for further development in future studies. Particular areas of interest include research on objective indicators of biological processes, or abnormalities in GWI associated with:
• Central nervous system structure and function, in particular, the role of glial cells, astrocytes, and microglia in GWI symptomatology
• Central neuroinflammatory processes
• Autonomic nervous system function
• Neuroendocrine measures
• Immune parameters/Indicators of chronic infection
• Gastrointestinal complaints/symptoms
• Genetic, genomic, proteomic, or metabolic characteristics
• Respiratory symptoms
• Sexual dysfunction
 
Value
Up to $600K plus indirect costs
 
Duration
Up to 3 years
 
Deadlines
Full application to ORS – July 10, 2012
Pre-application to agency – April 9, 2012, 5:00 p.m. Eastern Time (ET)
Full Application to agency (by invitation only) – July 24, 2012, 11:59 p.m. ET
 
Please consult the following web site for further information on this opportunity and how to apply:
http://cdmrp.army.mil/funding/pa/12gwirpiira_pa.pdf
 
2) Innovative Treatment Evaluation Award (ITEA) (Funding Opportunity No.: W81XWH-12-GWIRP-ITEA)
 
Objectives
This award is intended to support the initial evaluation of a treatment or intervention in smaller, early phase or pilot clinical trials (Phase II or I/II, devices in FDA Class I-III), and does not require preliminary data.  The ITEA supports the early systematic evaluation of innovative treatment interventions with the potential to impact the health and lives of veterans with GWI.  The results of preliminary studies funded by this award can provide proof of principle data, and support future development of broader efficacy studies of the proposed interventions.
 
Value
Up to $450K plus indirect costs
 
Duration
Up to 3 years
 
Deadlines
Full-application to ORS – July 10, 2012
Pre-application to agency – April 9, 2012, 5:00 p.m. Eastern time (ET)
Full application to agency (by invitation only) – July 24, 2012, 11:59 p.m. ET
 
Please consult the following web site for further information on this opportunity and how to apply:
http://cdmrp.army.mil/funding/pa/12gwirpitea_pa.pdf
 
3) Clinical Trial Award (CTA) (Funding Opportunity No.: W81XWH-12-GWIRP-CTA)
Objectives
This award is intended to support larger, more definitive (Phase II-III, FDA device class I-III) clinical trials.  The CTA supports execution of clinical trials with the potential to have a significant impact on the health and lives of veterans of GWI.  Health outcomes of interest should include effects of interventions on:
 
• Global health measures (biomarkers) and/or functional status
• Improvements in symptom complexes (e.g., cognitive function, musculoskeletal/pain symptoms, gastrointestinal symptoms, fatigue, respiratory problems, skin abnormalities, sleep difficulties), individually and as they may interact with each other
• GWI subgroups characterized by symptom or other clinical characteristics
 
Value
Up to $1.5M plus indirect costs
 
Duration
Up to 4 years
 
Deadlines
Full application to ORS – July 10, 2012
Pre-application to agency – April 9, 2012, 5:00 p.m. Eastern time (ET)
Full Application to agency (by invitation only) – July 24, 2012
 
Please consult the following web site for further information on this opportunity and how to apply:
http://cdmrp.army.mil/funding/pa/12gwirpcta_pa.pdf
 
MULTIPLE SCLEROSIS RESEARCH PROGRAM (MSRP)
 
1)      Idea Award (Funding Opportunity No.: W81XWH-12-MSRP-IA)
 
Objectives
·         To promote new ideas that are in the early stages of development and have the potential to yield high-impact findings and new avenues of investigation; and
·         To support conceptually innovative, high-risk/potentially high-reward research that could ultimately lead to critical discoveries in understanding the causes and progression of MS and/or improvements in patient care and/or quality of life.
 
Value
Up to $400K plus indirect costs
 
Duration
Up to 2 years
 
Deadlines
Full application to ORS – July 3, 2012
Pre-application to agency – April 24, 2012, 5:00 p.m. Eastern Time (ET)
Full Application to agency – July 17, 2012, 11:59 p.m. ET
 
Please consult the following web site for further information on this opportunity and how to apply:
http://cdmrp.army.mil/funding/pa/12msrpidea_pa.pdf
 
 
OVARIAN CANCER RESEARCH PROGRAM (OCRP)
 
1)      Outcomes Consortium Development Award (Funding Opportunity No.: W81XWH-12-OCRP-OCDA)
 
Objectives
·         To support a multi-institutional research effort conducted by leading ovarian cancer researchers and consumer advocates that specifically focuses on identifying and understanding predictors of disease outcomes in ovarian cancer patients; and
·         To focus on predictors of disease outcomes, particularly for ovarian cancer patients who are long-term survivors.
 
Value
Up to $400K plus indirect costs
 
Duration
Up to 2 years
 
Deadlines
Full application to ORS – July 19, 2012
Pre-application to agency – May 9, 2012, 5:00 p.m. Eastern Time (ET)
Full Application to agency – August 2, 2012, 11:59 p.m. ET
 
Please consult the following web site for further information on this opportunity and how to apply:
http://cdmrp.army.mil/funding/pa/12ocrpocda_pa.pdf

ORS Submission Policy
York University researchers are reminded that all applications for external research funding, including Letters of Intent, must be reviewed and approved by the Office of Research Services before they are submitted to the granting agency. For internal approval, the application must be accompanied by a completed ORS Checklist, which requires the Chair’s and Dean’s signatures.

To ensure that the approved application is ready by the agency deadline, a complete application folder must be submitted to the ORS ten (10) working days prior to final submission date.

Contact Us

Site Map

Privacy and Legal